pharma · Non-muscle Invasive Bladder Cancer · Non-Muscle Invasive Bladder Cancer
ImmunityBio
Immunitybio Ireland Limited
Immunitybio Ireland is a pharma organization headquartered in GB. Primary therapeutic focus areas include Non-muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer. NovaPharmaNews links 2 clinical program(s)
San Diego, USA HQ
2014 Founded
625 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2014
- Employees
- 625
- Programs
- 2
- Drugs
- 5
- Patents
- 0
BCG (50mg/instillation) + N-803 (400 μg/instillation)
Phase 2 · mab · Non-muscle Invasive Bladder Cancer
BCG (50mg/instillation) + N-803 (400 μg/instillation) for Non-muscle Invasive Bladder Cancer is a Phase 2 program (mab) at Immunitybio Ireland Limited with 1 ClinicalTrials.gov record(s).
Internal code CA-ALT-803-01-14; QUILT-2.005
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Immunitybio Ireland Limited
- Phase
- Phase 2
- Modality
- mab
- Indication
- Non-muscle Invasive Bladder Cancer
- Status
- active
- Trials
- 1